PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia
Journal of Gynecologic Oncology · 2023
DOI: 10.3802/jgo.2023.34.e53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von Yu Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Carcinoma, Endometrioid, Endometrial Hyperplasia. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE: This study aimed to investigate the impact of molecular classification and PTEN, KRAS and PIK3CA gene mutation on the outcome of fertility-preserving treatment in the patients with endometrioid endometrial cancer (EEC) and endometrial atypical hyperplasia (EAH). METHODS: This is a single-center retrospective study. A total of 135 patients with EEC and EAH receiving fertility-preserving treatment and molecular classification were reviewed. The distribution of the four types of molecular classification was described. The impact of non-specific molecular profile (NSMP), mismatch repair-deficiency (MMRd), and PTEN, KRAS and PIK3CA gene mutation on the outcome of fertility-preserving treatment was analyzed. RESULTS: Of the patients analyzed, 86.7% (117/136) were classified as having NSMP; 14 (10.4%), MMRd; 1 (0.7%), POLEmut EAH; and 3 (2.2%), p53abn EEC. The patients having NSMP and MMRd achieved similar 16-, 32-, and 48-week complete response rates. The patients harboring tier I and tier II PTEN mutations (PTENmut-Clin) achieved lower cumulative 32-week CR rates than those with PTEN-others (without PTENmut-Clin) (22/47, 46.8% vs. 50/74, 67.6%; p=0.023; odds ratio=0.422; 95% confidence interval [CI]=0.199-0.896). Insulin-resistance (hazard ratio [HR]=0.435; 95% CI=0.269-0.702; p=0.001) and PTENmut-Clin (HR=0.535; 95% CI=0.324-0.885; p=0.015) were independent negative predictors for lower 32-week CR rates. CONCLUSION: PTENmut-Clin is an independent risk factor for unfavorable fertility-preserving treatment outcomes in the patients with EEC and EAH. The patients with MMRd receiving fertility-preserving treatment achieved outcomes similar to those of the patients with NSMP. The molecular profiles might guide fertility-preserving treatment in the prognosis and clinical decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
- Shanghai Medical college, Fudan University, Shanghai, China.
- Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. xiaojunchen2013@sina.com.
ORCID-Profile: Yu Xue, Youting Dong, Yaochen Lou, Qiaoying Lv, Weiwei Shan, Chao Wang, Xiaojun Chen
Zitieren
APA
Xue, Y., Dong, Y., Lou, Y., Lv, Q., Shan, W., Wang, C., & Chen, X. (2023). PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e53
Vancouver
Xue Y, Dong Y, Lou Y, Lv Q, Shan W, Wang C, et al. PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e53
BibTeX
@article{Xue2023,
author = {Xue, Yu and Dong, Youting and Lou, Yaochen and Lv, Qiaoying and Shan, Weiwei and Wang, Chao and Chen, Xiaojun},
title = {PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia},
journal = {Journal of Gynecologic Oncology},
year = {2023},
doi = {10.3802/jgo.2023.34.e53}
}
EUVIMED